COMBINATION THERAPIES EMPLOYING ACE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DIABETIC DISORDERS
The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension.
1 . A method of treating or inhibiting hypertension in a diabetic patient comprising administering a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor and pyridoxal-5′-phosphate, pharmaceutically acceptable acid addition salts thereof, or mixtures thereof, wherein the pyridoxal-5′-phosphate is in a range of about 225 mg to about 500 mg per dose.
2 . The method according to claim 1 , wherein the ACE inhibitor is selected from a group consisting of benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and a mixture thereof.
3 . The method according to claim 1 , wherein the ACE inhibitor is lisinopril and the therapeutically effective amount of lisinopril is between 5 and 40 mg per day.
4 . The method according to claim 3 , wherein the therapeutically effective amount of lisinopril is 20 mg per day.
5 . The method according to claim 1 , wherein the ACE inhibitor is captopril.
6 . The method according to claim 1 , wherein the ACE inhibitor is enalapril.
7 . The method according to claim 1 , wherein the ACE inhibitor is ramipril.
8 . The method according to claim 1 , wherein the ACE inhibitor is trandolapril.
9 . The method according claim 1 , wherein the diabetic patient is an insulin dependent diabetic patient.
10 . The method according to claim 1 , wherein the diabetic patient is a non-insulin dependent diabetic patient.
11 . A method of controlling blood glucose or serum glucose in a diabetic patient comprising administering a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor and pyridoxal-5′-phosphate, pharmaceutically acceptable acid addition salts thereof, or mixtures thereof, wherein the pyridoxal-5′-phosphate is in a range of about 225 mg to about 500 mg per dose.
12 . The method according to claim 11 , wherein the ACE inhibitor is selected from a group consisting of benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and a mixture thereof.
13 . The method according to claim 11 , wherein the ACE inhibitor is lisinopril and the therapeutically effective amount of lisinopril is between 5 and 40 mg per day.
14 . The method according to claim 13 , wherein the therapeutically effective amount of lisinopril is 20 mg per day.
15 . The method according to claim 11 , wherein the ACE inhibitor is captopril.
16 . The method according to claim 11 , wherein the ACE inhibitor is enalapril.
17 . The method according to claim 11 , wherein the ACE inhibitor is ramipril.
18 . The method according to claim 11 , wherein the ACE inhibitor is trandolapril.
19 . The method according to claim 11 , wherein the diabetic patient is an insulin dependent diabetic patient.
20 . The method according to claim 11 , wherein the diabetic patient is a non-insulin dependent diabetic patient.